A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal Cancers

Trial Profile

A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal Cancers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Trametinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Rectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
    • 06 Jun 2017 Results (data cut off: 6 Feb 2017) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Status changed to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top